Get started
MARINUS PHARMACEUTICALS INC COM USD0.001(POST REV SPLT)MARINUS PHARMACEUTICALS INC COM USD0.001(POST REV SPLT)MARINUS PHARMACEUTICALS INC COM USD0.001(POST REV SPLT)

MARINUS PHARMACEUTICALS INC COM USD0.001(POST REV SPLT)

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0JYL trade ideas

MRNS short-term profit 75%!1) RSI will cut above its moving average soon but i will take position early because i applied 2 DEMA on prices(which are 5 period (red one) and 20 period (green one)). 2) When 2 DEMA cross each other i will take position a little bit early. 3) CCI cut above its moving average as you see but resistance line of CCI has not been broken yet. But next week it will be broken certainly. 4) I drew resistance line on Momentum, it is too far but it does not matter. It cut above its moving average like CCI. It is buy sign but prices did not increase. All comments do not include investing advice!
NASDAQ:MRNSLong
by Emirhanhmc
2
Marinus Pharmaceuticals, Inc. Rallying Pre-MarketMarinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
NASDAQ:MRNSLong
by DEXWireNews
Marinus Pharmaceuticals, Bullish breakout Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
NASDAQ:MRNSLong
by DEXWireNews
1
Plausible acquisition targetPotential near-term catalysts: - breakthrough therapy designation in RSE - end-of-PhII meetings for PPD and RSE - partnership or acquisition Thesis summary: Drug showed 100% seizure control at 24h in PhII trial in patients with drug-resistant, life-threatening seizures (RSE) Intravenous formulation of the drug showed strong anti-depressant activity but oral disappointed in a PhII trial. Oral setback likely a matter of patient compliance. Stock sold off with investors overlooking value of IV in severely depressed patients (think IV ketamine) and RSE. 2 PhIII trials ongoing in orphan pediatric conditions. Filed new patents in 2018 that should boost IP protection for the drug until 2038. Company chose not to raise cash following ++ RSE data release, suggesting ongoing partnership/acquisition talks. Key stats: - debt-free - cash through Q3 2020 - similar drug to SAGE at 1/100 the valuation
NASDAQ:MRNSLong
by PharmaTechHunter
Can MRNS go the distance this week?"On Tuesday, the company earned attention from analysts at H.C. Wainwright. The research firm initiated coverage on MRNS stock. It gave the company a “BUY” rating as well as a price target of $5 per share. This was the 3rd analyst firm to initiate coverage on the stock this year. Previous to H.C. Wainwright, Jefferies and Leerink Swann both initiated coverage with “BUY” and “Outperform” ratings, respectively, for the penny stock. The two other firms also..." 3 Penny Stocks Making New Highs In September NASDAQ:MRNS
NASDAQ:MRNS
by PennyStocks101
$MRNS On watchlist for a breakout on impending news possibly .The price action has been quite positive in the stock of NASDAQ:MRNS in 2019 gaining almost 65% from the oversold lows in December. Like all Pharmaceutical companies, trails results can move the stock incredibly fast, speculation and rumor has it that the stock is due for a considerable breakout WITH PLENTY OF UPSIDE POTENTIAL. A alert for a break above the 200ma could signal a nice entry while using FIB retracement levels as good price targets. SHORT INTEREST 9.44% AVERAGE ANALYSTS PRICE TARGET $16.06 AVERAGE ANALYSTS RECOMMENDATION BUY COMPANY PROFILE Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
NASDAQ:MRNS
by RedHotStocks
MARINUS - LongMARINUS is a leader in the development of neurosteroids for the treatment of depression. It is developing ganaxolone for PPD (Postpartum Depression). Topline data from a Phase 2 study should be available in H2. The stock price dropped after its Q earnings results. Its cash of $21.47M is solid to fund its operations and this is good for me. Technically the recent move down is within a 5 waves up pattern and I remain bullish. Price is testing the two important lines (long term EMAs) Therefore I am positive for this stock with a Target to the upside which is now set at the $10-12 area. Current prices are attractive for building a position at MRNS. Protection: A move below $5 will cancel the positive scenario and therefore this is the stop loss. An alternative Strategy: Instead of buying at current levels, wait until price strengthens, Buy above $7.5 with same target prices.
NASDAQ:MRNSLong
by winstox